Description
The purposes of this study is to examine efficacy of the IDEAL2 (Improving Diet and Exercise in ALL) caloricrestriction and activity intervention integrated into HR B-ALL induction to reduce incidence of end of induction (EOI) MRD ≥0.01%.
What to expect
CHOP and the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) consortium are conducting a study for children and young adults between the ages of 10 and 26 who are receiving induction therapy for NCI/Rome high-risk B-cell acute lymphoblastic leukemia (HR B-ALL). This study examines the efficacy of the IDEAL2 (Improving Diet and Exercise in ALL) caloric restriction and activity intervention integrated into HR B-ALL induction to reduce incidence of end of induction (EOI) MRD â¥0.01%. Subjects will be asked to come to CHOP for diet and exercise education, imaging scans, and questionnaires and will also wear a Fitbit activity monitor during the study. For more information about this study, including specific eligibility criteria, please visit clinicaltrials.gov and search for "NCT05082519" or visit the TACL website. To hear more about this and other available trails or get any questions answered please contact our Cancer Intake Specialist by phone at 267-426-0762 or email oncointake@chop.edu.
